In a recent study by Morel and colleagues, inhibition of EZH2 restored the expression of ISGs and reversed the resistance to ICB treatments, highlighting the therapeutic potential of EZH2 inhibitors in prostate cancer (51). The gene discussed is EZH2; the disease is prostate carcinoma.